ZIVO

NASDAQ

Zivo Bioscience Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

News25/Ratings1

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is based in Keego Harbor, Michigan.

News · 26 weeks16+50%

2025-10-262026-04-19

Mix1290d

Insider7(58%)
Other3(25%)
SEC Filings2(17%)

Latest news

25 items

17dPR
ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife™ Algal Biomass
Partnership with 40-Year Industry Leader Positions ZIVO to Meet Anticipated Global Commercial Demand Zivo Bioscience, Inc. (OTCQB:ZIVO) ("ZIVO" or the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the signing of a manufacturing agreement with Cyanotech Corporation to grow, cultivate and process ZIVO's proprietary algal biomass for its Zivolife™ product line. ZIVO is advancing Zivolife™ toward commercial applications across animal health, human nutrition and functional ingredients markets. This agreement with Cyanotech, one of the world's most establ
22dSEC
SEC Form EFFECT filed by Zivo Bioscience Inc.
EFFECT - Zivo Bioscience, Inc. (0001101026) (Filer)
24dSEC
Zivo Bioscience Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
27dPR
ZIVO Bioscience Provides Special Letter to Shareholders
ZIVO Bioscience, Inc. (OTCQB:ZIVO), today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Shareholders, I am writing to inform you of a significant and carefully considered decision by the Board of Directors of ZIVO Bioscience, Inc. ("ZIVO" or the "Company"): we intend to deregister the Company's securities with the Securities and Exchange Commission and cease public reporting. This letter explains the reasoning behind this decision, what it means for shareholders, and how it positions ZIVO for its next phase of growth. A Decision Made in the Best Interests of Shareholders After careful deliberation, we have
51dINSIDER
Director Yaldoo Laith L bought $14,998 worth of shares (1,543 units at $9.72) (SEC Form 4)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
55dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Zivo Bioscience Inc.
SCHEDULE 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)
65dINSIDER
Large owner Strome Mark E bought $195,400 worth of shares (20,000 units at $9.77) (SEC Form 4)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
70dINSIDER
Director Yaldoo Laith L bought $24,997 worth of shares (2,434 units at $10.27) (SEC Form 4)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
85dINSIDER
Director Cornell Alison A bought $99,995 worth of shares (11,709 units at $8.54), increasing direct ownership by 4% to 279,481 units (SEC Form 4)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
85dINSIDER
President and CEO Payne John Bernard bought $99,995 worth of shares (11,709 units at $8.54), increasing direct ownership by 148% to 19,618 units (SEC Form 4)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
86dINSIDER
Director Maggiore Christopher D. bought $14,993 worth of shares (1,766 units at $8.49), increasing direct ownership by 0.34% to 519,292 units (SEC Form 4)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
86dINSIDER
Director Yaldoo Laith L bought $14,993 worth of shares (1,766 units at $8.49) (SEC Form 4)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
115dINSIDER
New insider Sullivan William A. claimed no ownership of stock in the company (SEC Form 3)
3 - Zivo Bioscience, Inc. (0001101026) (Issuer)
121dSEC
Zivo Bioscience Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
142dINSIDER
Director Yaldoo Laith L bought $24,993 worth of shares (2,777 units at $9.00) (SEC Form 4)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
160dSEC
SEC Form 10-Q filed by Zivo Bioscience Inc.
10-Q - Zivo Bioscience, Inc. (0001101026) (Filer)
185dINSIDER
Large owner Strome Mark E bought $249,996 worth of shares (20,259 units at $12.34) (SEC Form 4)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
191dINSIDER
Director Yaldoo Laith L bought $19,991 worth of shares (1,659 units at $12.05) (SEC Form 4)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
196dINSIDER
Director Maggiore Christopher D. bought $284,421 worth of shares (23,682 units at $12.01), increasing direct ownership by 5% to 517,526 units (SEC Form 4)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
199dINSIDER
SEC Form 4 filed by Director Yaldoo Laith L
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
199dINSIDER
SEC Form 4 filed by Director Maggiore Christopher D.
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
199dINSIDER
SEC Form 4 filed by Director Cornell Alison A
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
203dINSIDER
Director Yaldoo Laith L bought $244,999 worth of shares (15,322 units at $15.99) (SEC Form 4)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
225dSEC
Zivo Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
225dPR
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
ZIVO Bioscience, Inc. (OTCQB:ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Shareholders, I am pleased to provide you with this important update on the significant progress by ZIVO Bioscience and a review of our exciting future direction. Quite simply, this past year has been one of the most pivotal in our history. Our proprietary algae platform has delivered breakthrough results that position ZIVO at the forefront of two rapidly growing markets – human nutrit